ICS/LABA exacerbation benefit outweighs pneumonia risk

LONDON – The benefit of a fixed-dose inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination in reducing exacerbations of chronic obstructive pulmonary disease (COPD) far...
Source: Hospitalist News - Category: Hospital Management Source Type: research